784
Views
3
CrossRef citations to date
0
Altmetric
Special Issue: Recent advances in isoprenoid studies

Suppression of phenotype of Escherichia coli mutant defective in farnesyl diphosphate synthase by overexpression of gene for octaprenyl diphosphate synthase

, , , , , , & show all
Pages 1003-1010 | Received 28 Aug 2017, Accepted 13 Oct 2017, Published online: 01 Dec 2017

Figures & data

Figure 1. Biosynthesis of isoprenoids in Escherichia coli.

Figure 1. Biosynthesis of isoprenoids in Escherichia coli.

Table 1. Bacterial strains used in this study.

Figure 2. Restriction maps of the plasmids used in this study. Boxes denote the vector regions. The small arrowheads and the gray areas in the boxes denote the promoters and vector-derived coding regions for hexahistidine tags. Large solid arrows denote the coding regions of the ispA, ispB, and ispU/rth genes. Small arrows denote primer binding sites for PCR. Abbreviations: E, EcoRI site; H, HindIII site; S, SalI site; V, EcoRV site; Plac, lac promoter; Ptrc, trc promoter.

Figure 2. Restriction maps of the plasmids used in this study. Boxes denote the vector regions. The small arrowheads and the gray areas in the boxes denote the promoters and vector-derived coding regions for hexahistidine tags. Large solid arrows denote the coding regions of the ispA, ispB, and ispU/rth genes. Small arrows denote primer binding sites for PCR. Abbreviations: E, EcoRI site; H, HindIII site; S, SalI site; V, EcoRV site; Plac, lac promoter; Ptrc, trc promoter.

Table 2. Growth rates of strains and transformants used in this study.

Figure 3. The level of farnesyl diphosphate (FPP) in strains and transformants used in this study. SF5 (the wild-type strain), SF7N (the ispA-null mutant), SF7N harboring pHT1 (which carries ispA), and SF7N harboring pKA5 (which carries ispB) were used for the quantification of FPP. Bar graphs show averages of three assays. Error bars show standard deviations. The statistical significance is indicated (*p < 0.05 compared with SF7N; **p < 0.01 compared with SF7N).

Figure 3. The level of farnesyl diphosphate (FPP) in strains and transformants used in this study. SF5 (the wild-type strain), SF7N (the ispA-null mutant), SF7N harboring pHT1 (which carries ispA), and SF7N harboring pKA5 (which carries ispB) were used for the quantification of FPP. Bar graphs show averages of three assays. Error bars show standard deviations. The statistical significance is indicated (*p < 0.05 compared with SF7N; **p < 0.01 compared with SF7N).

Figure 4. High-performance liquid chromatography-mass spectrometry analysis of the ubiquinone fraction of SF7N. (A) Chromatogram of absorbance detected at 275 nm. Peak a, ubiquinone-8; peak b, ubiquinone-9; peak c, ubiquinone-10. (B) Mass spectrum of peak b.

Figure 4. High-performance liquid chromatography-mass spectrometry analysis of the ubiquinone fraction of SF7N. (A) Chromatogram of absorbance detected at 275 nm. Peak a, ubiquinone-8; peak b, ubiquinone-9; peak c, ubiquinone-10. (B) Mass spectrum of peak b.

Figure 5. The level of isoprenoid quinones and undecaprenyl phosphate in transformants of ispA null mutant E. coli strain SF7N. The transformants of SF7N, harboring pCL1921 (empty vector), pHT1 (which carries ispA), pKA5 (which carries ispB), and pEDA5 (which carries ispU/rth) were used for the analysis of isoprenoids. Bar graphs show averages of three assays. Error bars show standard deviations. The statistical significance is indicated (**p < 0.01 compared with SF7N/pCL1921). Abbreviations: UQ-8, ubiquinone-8; UQ-9, ubiquinone-9; MK-8, menaquinone-8; UP, undecaprenyl phosphate.

Figure 5. The level of isoprenoid quinones and undecaprenyl phosphate in transformants of ispA null mutant E. coli strain SF7N. The transformants of SF7N, harboring pCL1921 (empty vector), pHT1 (which carries ispA), pKA5 (which carries ispB), and pEDA5 (which carries ispU/rth) were used for the analysis of isoprenoids. Bar graphs show averages of three assays. Error bars show standard deviations. The statistical significance is indicated (**p < 0.01 compared with SF7N/pCL1921). Abbreviations: UQ-8, ubiquinone-8; UQ-9, ubiquinone-9; MK-8, menaquinone-8; UP, undecaprenyl phosphate.

Table 3. Activity of hexahistidine-tagged octaprenyl diphosphate synthase.

Figure 6. Autoradiograms of thin layer chromatography (TLC) of prenyl alcohols obtained by enzymatic hydrolysis. Reaction of [1-14C]IPP and DMAPP was catalyzed by purified hexahistidine-tagged IspB. The products were extracted with butanol and treated with acid phosphatase. The resulting polyprenols were extracted with hexane and analyzed by normal phase TLC on a silica gel 60 plate using benzene-ethyl acetate (4:1 v/v) (A) and by reversed phase TLC on an LKC-18 plate using acetone-water (9:1 v/v) (B). Abbreviations: Ori, Origin; SF, solvent front; C15, E,E-farnesol; C20, E,E,E-geranylgeraniol; C45, solanesol (all-E-nonaprenol); C50, ficaprenol-50 (Z,E-mixed decaprenol); C55, ficaprenol-55 (Z,E-mixed undecaprenol); C60, ficaprenol-60 (Z,E-mixed dodecaprenol).

Figure 6. Autoradiograms of thin layer chromatography (TLC) of prenyl alcohols obtained by enzymatic hydrolysis. Reaction of [1-14C]IPP and DMAPP was catalyzed by purified hexahistidine-tagged IspB. The products were extracted with butanol and treated with acid phosphatase. The resulting polyprenols were extracted with hexane and analyzed by normal phase TLC on a silica gel 60 plate using benzene-ethyl acetate (4:1 v/v) (A) and by reversed phase TLC on an LKC-18 plate using acetone-water (9:1 v/v) (B). Abbreviations: Ori, Origin; SF, solvent front; C15, E,E-farnesol; C20, E,E,E-geranylgeraniol; C45, solanesol (all-E-nonaprenol); C50, ficaprenol-50 (Z,E-mixed decaprenol); C55, ficaprenol-55 (Z,E-mixed undecaprenol); C60, ficaprenol-60 (Z,E-mixed dodecaprenol).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.